Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
10 results
D1.102 - Md
D1.88 - Mepolizumab and intestinal parasitic infection: A case report
D1.91 - Baseline characteristics and main clinical outcomes of patients receiving tezepelumab in the framework of use in Special Situations prior to commercialization in Spain (T-ROSS Study)
D1.92 - Results from the EGPAware Delphi study on Red Flags for Suspicion of Eosinophilic Granulomatosis with Polyangiitis (EGPA): current management in Europe
D1.93 - ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up
D1.94 - Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients
D1.95 - Dupilumab-induced eosinophilia: a transient effect
D1.96 - Impact of Dupilumab-induced Eosinophilia on Pulmonary Function Tests and Patient Reported Outcomes Measures (PROMs)
D1.99 - Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP
D1.405 - Immunological imprinting of IgG response to RV VP1 in children of the MAS and PAPS birth cohorts
Download the app
The congress at your fingertips
Available on
Download